期刊名称：The Open Pharmacoeconomics & Health Economics Journal
电子版ISSN：1876-8245
出版年度：2011
卷号：3
期号：1
页码：6-10
DOI：10.2174/1876824501103010006
出版社：Bentham open
摘要： In Finland, the drug retail prices are determined with a regressive pharmaceutical pricing scheme (PPS) that
leads to higher absolute sales margins for products with higher wholesale prices. At the same time low-priced products are
sold at prices below the true costs of drug delivery. Despite these characteristics retail prices are used to represent all drug
costs in health economic evaluations that are required before societal reimbursement of new drugs can be granted. We
assessed the impact of PPS induced cost differences on the results of cost-utility analyses in hypothetical examples. The
examples show that the Finnish PPS worsens the ICERs obtained for more expensive pharmaceuticals. The Finnish PPS is
problematic when the aim is to provide Finnish patients with optimal, cost-effective treatments. In its current form, the
PPS discourages innovation and comparability of results with other settings, and may prevent reimbursement of otherwise
cost-effective treatments.
